Physician profile
Robert B Moricca
NPI 1902815822
$13,257.66
in general payments reported to CMS, 2019-2025
43 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,341 · 2020: $1,490 · 2021: $1,948 · 2022: $2,127 · 2023: $2,376 · 2024: $2,863 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,352.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,761.47 | 2019-2024 | Ofev, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,802.56 | 2019-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,760.71 | 2019-2024 | Fasenra, Breztri, Airsupra |
| Mylan Specialty L.P. | $1,170.10 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $861.04 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $749.10 | 2019-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $698.67 | 2021-2024 | Hyqvia, Cuvitru |
| Amgen INC. | $361.63 | 2021-2024 | Tezspire |
| Baxter Healthcare | $273.78 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Genentech USA, INC. | $228.31 | 2019-2023 | Xolair |
| Electromed, INC. | $196.36 | 2019-2024 | Smartvest |
| Janssen Pharmaceuticals, INC | $183.16 | 2020-2024 | Xarelto |
| Vifor Pharma, INC. | $173.70 | 2024 | Zemaira |
| Abbvie INC. | $165.74 | 2024 | |
| Sunovion Pharmaceuticals INC. | $157.34 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $155.56 | 2019-2025 | Vest Therapy Und |
| Insmed, INC. | $140.39 | 2019-2021 | |
| Genzyme Corporation | $131.25 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $116.24 | 2020-2024 | Nuzyra |
| Pfizer INC. | $111.97 | 2021-2022 | |
| Advanced Respiratory, INC | $111.63 | 2019-2021 | |
| United Therapeutics Corporation | $89.45 | 2022-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $70.61 | 2019-2024 | Capvaxive |
| Covis Pharma Gmbh | $65.94 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $63.71 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $58.42 | 2019-2024 | Uptravi, Opsumit |
| Stryker Corporation | $52.99 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pulmonx Corporation | $49.65 | 2019-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Ani Pharmaceuticals, INC. | $49.59 | 2024 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $48.62 | 2020 | |
| Inari Medical, INC. | $47.19 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Gilead Sciences, INC. | $45.70 | 2024 | |
| Sanofi Pasteur INC. | $39.35 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $36.53 | 2019-2021 | |
| Csl Behring | $35.14 | 2019 | |
| Harmony Biosciences LLC | $29.30 | 2022 | |
| Zoll Respicardia, INC. | $29.10 | 2024-2025 | Remede System |
| Inspire Medical Systems, INC. | $27.37 | 2023 | Inspire |
| Seqirus USA INC | $24.97 | 2024 | Fluad, Flucelvax |
| Shionogi INC | $23.74 | 2021 | |
| Shire North American Group INC | $23.17 | 2019 | |
| Endogastric Solutions, INC | $20.42 | 2019 | |
| Aytu Biopharma, INC. | $15.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moricca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.